Compare Stocks: EBS, JNJ, OMER, and NKTR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$6.95 +0.5%	$6.06	$4.36 ▼ $14.06	$357.35M	2.28	967,778 shs	253,244 shs
JNJ Johnson & Johnson	$252.03 +1.4%	$265.89	$184.66 ▼ $281.07	$607.41B	0.21	7.97 million shs	3.82 million shs
NKTR Nektar Therapeutics	$36.92 -2.6%	$65.23	$33.40 ▼ $109.00	$1.26B	1.26	1.11 million shs	394,095 shs
OMER Omeros	$18.88 0.0%	$18.12	$6.24 ▼ $21.24	$1.37B	2.57	1.65 million shs	322,052 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	-0.42%	+0.17%	+11.00%	-11.92%	-25.42%
JNJ Johnson & Johnson	-5.72%	-2.33%	-6.40%	+0.55%	+30.40%
NKTR Nektar Therapeutics	-4.82%	-4.99%	-45.64%	-44.48%	-33.94%
OMER Omeros	-3.82%	+2.00%	+3.28%	+82.06%	+350.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$6.95 +0.5%	$6.06	$4.36 ▼ $14.06	$357.35M	2.28	967,778 shs	253,244 shs
JNJ Johnson & Johnson	$252.03 +1.4%	$265.89	$184.66 ▼ $281.07	$607.41B	0.21	7.97 million shs	3.82 million shs
NKTR Nektar Therapeutics	$36.92 -2.6%	$65.23	$33.40 ▼ $109.00	$1.26B	1.26	1.11 million shs	394,095 shs
OMER Omeros	$18.88 0.0%	$18.12	$6.24 ▼ $21.24	$1.37B	2.57	1.65 million shs	322,052 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	-0.42%	+0.17%	+11.00%	-11.92%	-25.42%
JNJ Johnson & Johnson	-5.72%	-2.33%	-6.40%	+0.55%	+30.40%
NKTR Nektar Therapeutics	-4.82%	-4.99%	-45.64%	-44.48%	-33.94%
OMER Omeros	-3.82%	+2.00%	+3.28%	+82.06%	+350.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent Biosolutions	2.17	Hold	$10.00	43.99% Upside
JNJ Johnson & Johnson	2.80	Moderate Buy	$273.61	8.56% Upside
NKTR Nektar Therapeutics	2.69	Moderate Buy	$130.67	253.92% Upside
OMER Omeros	2.71	Moderate Buy	$34.00	80.13% Upside

Current Analyst Ratings Breakdown

Latest EBS, JNJ, OMER, and NKTR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/14/2026	JNJ Johnson & Johnson	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$272.00
10/14/2026	JNJ Johnson & Johnson	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$282.00 ➝ $275.00
10/14/2026	JNJ Johnson & Johnson	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$270.00
10/14/2026	JNJ Johnson & Johnson	Sanford C. Bernstein Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Perform
10/14/2026	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$290.00 ➝ $280.00
10/14/2026	OMER Omeros	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$22.00
10/12/2026	NKTR Nektar Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight ➝ Neutral	$53.00
10/12/2026	NKTR Nektar Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
10/12/2026	NKTR Nektar Therapeutics	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$130.00
10/9/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$178.00
10/9/2026	NKTR Nektar Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Market Perform

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent Biosolutions	$742.90M	0.48	$3.64 per share	1.91	$9.95 per share	0.70
JNJ Johnson & Johnson	$94.19B	6.45	$13.49 per share	18.68	$33.85 per share	7.45
NKTR Nektar Therapeutics	$55.23M	22.82	N/A	N/A	$4.41 per share	8.37
OMER Omeros	N/A	N/A	$1.80 per share	10.49	($1.71) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent Biosolutions	$52.60M	-$3.55	N/A	9.39	N/A	-22.95%	16.35%	6.17%	11/4/2026 (Estimated)
JNJ Johnson & Johnson	$26.80B	$8.63	29.21	20.44	2.70	21.48%	32.42%	13.35%	N/A
NKTR Nektar Therapeutics	-$164.08M	-$6.70	N/A	N/A	N/A	-287.84%	-37.87%	-25.67%	11/5/2026 (Estimated)
OMER Omeros	-$3.35M	$1.28	14.78	15.60	N/A	N/A	-164.92%	69.41%	11/12/2026 (Estimated)

Latest EBS, JNJ, OMER, and NKTR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	NKTR Nektar Therapeutics	-$2.07	N/A	N/A	N/A	$10.27 million	N/A
11/4/2026	Q3 2026	EBS Emergent Biosolutions	-$0.37	N/A	N/A	N/A	$123.22 million	N/A
10/13/2026	Q3 2026	JNJ Johnson & Johnson	$2.53	$2.59	+$0.06	$0.09	$25.38 billion	$25.40 billion
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	-$1.23	+$0.74	-$1.23	$10.43 million	$10.13 million
8/12/2026	Q2 2026	OMER Omeros	-$0.2683	$0.02	+$0.2883	$0.15	$12.69 million	$28.53 million
8/5/2026	Q2 2026	EBS Emergent Biosolutions	-$0.0850	$0.60	+$0.6850	-$3.49	$177.50 million	$234.30 million
7/15/2026	Q2 2026	JNJ Johnson & Johnson	$2.84	$2.90	+$0.06	$2.27	$25.06 billion	$25.31 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$5.36	2.13%	+5.25%	62.11%	64 Years
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A

Latest EBS, JNJ, OMER, and NKTR Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/13/2026	JNJ Johnson & Johnson	quarterly	$1.34	2.15%	11/24/2026	11/24/2026	12/8/2026
7/15/2026	JNJ Johnson & Johnson	quarterly	$1.34	1.96%	8/25/2026	8/25/2026	9/8/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent Biosolutions	1.70	5.42	2.95
JNJ Johnson & Johnson	0.44	1.09	0.81
NKTR Nektar Therapeutics	N/A	10.42	10.42
OMER Omeros	N/A	1.95	1.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent Biosolutions	78.40%
JNJ Johnson & Johnson	69.55%
NKTR Nektar Therapeutics	75.88%
OMER Omeros	48.79%

Insider Ownership

Company	Insider Ownership
EBS Emergent Biosolutions	6.00%
JNJ Johnson & Johnson	0.16%
NKTR Nektar Therapeutics	2.50%
OMER Omeros	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent Biosolutions	900	51.27 million	48.20 million	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.41 billion	Optionable
NKTR Nektar Therapeutics	63	34.14 million	33.29 million	Optionable
OMER Omeros	175	72.39 million	64.79 million	Optionable

EBS, JNJ, OMER, and NKTR Headlines

Recent News About These Companies

Omeros (NASDAQ:OMER) Stock Keeps "Overweight" Rating at Cantor Fitzgerald

4 hours ago | marketbeat.com

Omeros (NASDAQ:OMER) Stock Price Breaks Above 200 Day Moving Average - Here's What Happened

October 13 at 1:59 AM | marketbeat.com

Cantor Fitzgerald upgraded Omeros to Overweight for Omeros stock

October 8, 2026 | ad-hoc-news.deA

Omeros Corporation (NASDAQ:OMER) Stock Now Rated "Moderate Buy" by Wall Street Analysts

October 4, 2026 | americanbankingnews.com

Omeros Corporation (NASDAQ:OMER) Stock Has Consensus Target Price of $34.00

October 4, 2026 | marketbeat.com

Omeros consensus price target cut by 16.67% to $37.40

October 3, 2026 | msn.com

Inside the bitter father-son feud that unravelled the Omeros Bros seafood dynasty - as the tax office winds up the iconic Gold Coast eatery

October 2, 2026 | dailymail.comD

‘Devastated’ Omeros Bros patriarch disowns children as iconic Gold Coast restaurant collapses

October 1, 2026 | themercury.com.auT

Bank of America Corp DE Acquires 194,140 Shares of Omeros Corporation $OMER

October 1, 2026 | marketbeat.com

Omeros Corporation $OMER Shares Sold by Corient Private Wealth LP

September 29, 2026 | marketbeat.com

Omeros Corporation stock falls 3.28 percent while analysts target USD 22.00

September 28, 2026 | ad-hoc-news.deA

Omeros Corporation $OMER Shares Purchased by State Street Corp

September 26, 2026 | marketbeat.com

Omeros stock slips 1.47 percent after Cantor upgrade

September 25, 2026 | ad-hoc-news.deA

Il VP finanziario di Omeros David Borges vende azioni per $419.000

September 25, 2026 | it.investing.com

Omeros (NASDAQ:OMER) Stock: Insider David Borges Sells 10,000 Shares

September 25, 2026 | insidertrades.com

Omeros (NASDAQ:OMER) CAO Sells 10,000 Shares of Company Stock

September 24, 2026 | marketbeat.com

NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?

September 23, 2026 | finance.yahoo.com

Cantor Fitzgerald upgrades Omeros to overweight from neutral

September 23, 2026 | msn.com

Omeros Corporation stock hits 52-week high at 19.75 USD

September 22, 2026 | uk.investing.com

Omeros Shares Rise After Cantor Fitzgerald Upgrade

September 22, 2026 | finance.yahoo.com

Omeros upgraded at Cantor on Yartemlea opportunity

September 22, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EBS, JNJ, OMER, and NKTR Company Descriptions

Emergent Biosolutions NYSE:EBS

$6.94 +0.04 (+0.51%)

As of 12:44 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Johnson & Johnson NYSE:JNJ

$252.03 +3.42 (+1.37%)

As of 12:44 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Nektar Therapeutics NASDAQ:NKTR

$36.92 -1.00 (-2.64%)

As of 12:44 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Omeros NASDAQ:OMER

$18.88 -0.01 (-0.03%)

As of 12:44 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EBS, JNJ, OMER, and NKTR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EBS, JNJ, OMER, and NKTR Earnings

Compare Dividends

Latest EBS, JNJ, OMER, and NKTR Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EBS, JNJ, OMER, and NKTR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EBS, JNJ, OMER, and NKTR Company Descriptions

Emergent Biosolutions NYSE:EBS

Johnson & Johnson NYSE:JNJ

Nektar Therapeutics NASDAQ:NKTR

Omeros NASDAQ:OMER

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools